Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

New experimental pill, daraxonrasib, nearly doubled survival in metastatic pancreatic cancer patients, offering hope for a ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and ...

Opportunities in the Medullary Thyroid Cancer market arise from diverse pipeline developments by 8+ companies. Focus areas include novel therapies like Regorafenib and next-gen RET inhibitors ...

Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, announced results from two Phase 1/2 clinical trials evaluating ...

Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...

This retrospective cohort analysis evaluates the prevalence of brain metastases in patients with advanced nonanaplastic thyroid cancer to determine the clinical utility of routine neurological ...

Dr. Kyaw Zin Thein was in the middle of a difficult conversation. His patient — a man in his 70s — was running out of options ...

Navigating a cancer diagnosis often begins with a simple online search. The new Cancer Search Bar series from CURE brings those commonly searched questions directly to oncology ex ...